Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 11, 2011, Pages 2620-2627

  Grassi, Guido ^a   Seravalle, Gino ^b   Ghiadoni, Lorenzo ^c   Tripepi, Giovanni ^d   Bruno, Rosa Maria ^a   Mancia, Giuseppe ^a   Zoccali, Carmine ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONFOUNDING VARIABLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HUMAN; MALE; NEUROGRAPHY; POSTGANGLIONIC NERVE; PROTEINURIA; RISK FACTOR; SYMPATHETIC NERVE;

AGED; AGED, 80 AND OVER; ARGININE; BIOLOGICAL MARKERS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ITALY; KIDNEY; KIDNEY DISEASES; LINEAR MODELS; MALE; PROTEINURIA; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYMPATHETIC FIBERS, POSTGANGLIONIC; VENTRICULAR REMODELING;

EID: 80655126755     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06970711     Document Type: Article

References (38)

1. Zhang QL, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 8: 117, 2008.
2. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152, 2000
3. Zoccali C: Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective. Kidney Int 70: 26-33, 2006
4. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment. Kidney Int 65: 1568-1576, 2004
5. Grassi G: Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 23: 1052-1058, 2010
6. Ritz E, Amann K, Fliser D: The sympathetic nervous system and the kidney: Its importance in renal diseases. Blood Press Suppl 3: 14-19, 1998
7. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: A cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 46: 186-202, 2005
8. Mallamaci F, Tripepi G, Maas R, Malatino L, Boger R, Zoccali C: Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 15: 435-441, 2004
9. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ: Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 39: 683-688, 2002
10. Augustyniak RA, Victor RG, Morgan DA, Zhang W: L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol 290: R726-R732, 2006
11. Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992
12. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12: 2427-2433, 2001
13. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 106: 1974-1979, 2002
14. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ: Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14: 3239-3244, 2003
15. Park J, Campese VM, Nobakht N, Middlekauff HR: Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 105: 1873-1876, 2008
16. Grassi G, Quarti-Trevano F, Seravalle G, Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell'Oro R, Mancia G: Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 57: 846-851, 2011
17. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS, CREED investigators: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40: 41-46, 2002
18. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R, CREED investigators: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62: 339-345, 2002
19. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Boger RH: Determination of asymmetric dim-ethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 42: 1377-1383, 2004
20. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 55: 613-618, 1977
21. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5: 2024-2031, 1995
22. Kraemer HC, Stice E, Kazdin A, Offord D, Kupfer D: How do risk factors work together? Mediators, moderators, and independent, overlapping, and proxy risk factors. Am J Psychiatry 158: 848-856, 2001
23. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 17: 609-615, 2008
24. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 16: 2449-2455, 2005
25. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16: 2456-2461, 2005
26. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ: Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 27: 1341-1349, 2009
27. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, Orth SR, Ehmke H, Rump LC, Ritz E: Glomerulosclerosis and progression: Effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60: 1309-1323, 2001
28. Veelken R, Vogel EM, Hilgers K, Amann K, Hartner A, Sass G, Neuhuber W, Tiegs G: Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 19: 1371-1378, 2008
29. Chen Y, Lipkowitz MS, Salem RM, Fung MM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, Hicks PJ, Bowden DW, Freedman BI, Brophy VH, O'Connor DT, AASK: Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis. Am J Nephrol 32: 23-30, 2010
30. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340: 1321-1328, 1999
31. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14: 425-430, 2003
32. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Axelsson J: Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA: A novel pathophysiological pathway? Nephrol Dial Transplant 25: 3250-3256, 2010
33. Burns J, Sivananthan MU, Ball SG, Mackintosh AF, Mary DA, Greenwood JP: Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension. Circulation 115: 1999-2005, 2007
34. Siddiqi L, Prakken NH, Velthuis BK, Cramer MJ, Oey PL, Boer P, Bots ML, Blankestijn PJ: Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 25: 3272-3277, 2010
35. Shi B, Ni Z, Zhou W, Yu Z, Gu L, Mou S, Fang W, Wang Q, Cao L, Yan Y, Qian J: Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med 21: 444-448, 2010
36. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y, Minamino T, Asanuma H, Sanada S, Kim J, Kitamura S, Tomoike H, Hori M, Kitakaze M: Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110: 692-699, 2004
37. Alfieri AB, Briceno L, Fragasso G, Spoladore R, Palloshi A, Bassanelli G, Montano C, Arioli F, Cuko A, Ruotolo G, Margonato A: Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. J Cardiovasc Pharmacol 52: 49-54, 2008
38. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabrò R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 41: 1438-1444, 2003